Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1

Read full text
Authors: Rahul Banerjee, Matthew C. Cheung, Benjamin A. Derman, Hans Messersmith, Samer Al Hadidi, Sita Bhella, Cynthia Chmielewski, Mohammad S. Ebraheem, C Todd Kennedy, Shaji Kumar, Alan Langerak, Brea Lipe
+9 more Hira Mian, Eloísa Riva, Rahul Seth, Latha Subramanian, Saad Z. Usmani, Tanya M. Wildes, Saurabh Zanwar, Ying Zhuo, Lisa K. Hicks
Cited by: 1
References: 15

Abstract

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found on the ASCO Publications website .

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Clinical practice guidelines implementation Lung Cancer Research Studies

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
22
Pages
e113–e124
Publication date
20 May 2026
Language
EN